Skip to main content
For Healthcare Professionals
Spevigo_Logo
Spevigo-Home-banner-background

SPEVIGO® is the only EMA-approved treatment for GPP flares1,2

Unregulated IL-36R signalling leads to a neutrophilic inflammatory response in GPP3-6

  • The IL-36 pathway is regulated by the interplay between IL-36 agonists and antagonists to ensure a balanced immune response7,8

SPEVIGO® is the only treatment to block the key inflammatory pathway in GPP by targeting the IL-36 receptor1,2,9

  • SPEVIGO® is a humanised antagonistic monoclonal antibody that binds to the IL-36R and blocks activation by cognate ligands1
  • Unlike TNF-α and IL-17 inhibition, by inhibiting the IL-36R, SPEVIGO® blocks downstream inflammatory and pro-fibrotic pathways simultaneously10,11

See how SPEVIGO® works

The clinical significance of the preclinical studies characterising the MOA of SPEVIGO® is unknown.

EMA=European Medicines Agency; GPP=Generalized Pustular Psoriasis; IL=interleukin; IL-36R=interleukin-36 receptor; MOA=mechanism of action; TNF=tumour necrosis factor.

References

  1. Local SPEVIGO® Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals, Inc; June 2023.

  2. Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563

  3. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4):645-652. doi:10.1189/jlb.3RI1014-495R

  4. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(77):620-628. doi:10.1056/NEJMoa1013068

  5. Navarini AA, Burden AD, Capon F, et al; for the ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386

  6. Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5-13. doi:10.2340/00015555-2808

  7. Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines. Immunol Rev. 2018;281(1):169-178. doi:10.1111/imr.12610

  8. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428-2437. doi:10.1038/jid.2011.234

  9. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056

  10. Melton E, Hongyu Q. Interleukin-36 cytokine/receptor signaling: a new target for tissue fibrosis. Int J Mol Sci. 2020;21(18):6458. doi:10.3390/ijms21186458

  11. Elias M, Zhao S, Le HT, et al. IL-36 in chronic inflammation and fibrosis — bridging the gap? J Clin Invest. 2021;131(2):e144336. doi:10.1172/JCI144336